Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter

T. Komata, Y. Kondo, T. Kanzawa, S. Hirohata, S. Koga, H. Sumiyoshi, Satoshi Hirohata, B. P. Barna, I. M. Germano, M. Takakura, M. Inoue, E. S. Alnemri, J. W. Shay, S. Kyo, S. Kondo

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

Because the apoptotic pathway is often disrupted in tumor cells, its genetic restoration is a very attractive approach for the treatment of tumors. To treat malignant gliomas with this approach, it would be preferred to restrict induction of apoptosis to tumor cells by establishing a tumor-specific expression system. Telomerase is an attractive target because the vast majority of malignant gliomas have telomerase activity whereas normal brain cells do not. Activation of telomerase is tightly regulated at the transcriptional level of the telomerase catalytic subunit [human telomerase reverse transcriptase, (hTERT)]. Therefore, we hypothesized that using a hTERT promoter-driven vector system, an apoptosis-inducible gene may be preferentially restricted to telomerase- or hTERT-positive tumor cells. In this study, we constructed an expression vector consisting of the constitutively active caspase-6 (rev-caspase-6) under the hTERT promoter (hTERT/rev-caspase-6) and then investigated its antitumor effect on malignant glioma cells. The rationale for using the rev-caspase-6 gene is because it induces apoptosis independent of the initiator caspases. We demonstrated that the hTERT/rev-caspase-6 construct induced apoptosis in hTERT-positive malignant glioma cells, but not in hTERT-negative astrocytes, fibroblasts, and alternative lengthening of telomeres cells. In addition, the growth of s.c. tumors in nude mice was significantly suppressed by the treatment with hTERT/rev-caspase-6 construct. The present results strongly suggest that the telomerase-specific transfer of the rev-caspase-6 gene under the hTERT promoter is a novel targeting approach for the treatment of malignant gliomas.

Original languageEnglish
Pages (from-to)5796-5802
Number of pages7
JournalCancer Research
Volume61
Issue number15
Publication statusPublished - Aug 1 2001
Externally publishedYes

Fingerprint

Caspase 6
Telomerase
Glioma
Genes
Apoptosis
Neoplasms
Initiator Caspases
Telomere Homeostasis
human TERT protein
Nude Mice
Astrocytes
Fibroblasts

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. / Komata, T.; Kondo, Y.; Kanzawa, T.; Hirohata, S.; Koga, S.; Sumiyoshi, H.; Hirohata, Satoshi; Barna, B. P.; Germano, I. M.; Takakura, M.; Inoue, M.; Alnemri, E. S.; Shay, J. W.; Kyo, S.; Kondo, S.

In: Cancer Research, Vol. 61, No. 15, 01.08.2001, p. 5796-5802.

Research output: Contribution to journalArticle

Komata, T, Kondo, Y, Kanzawa, T, Hirohata, S, Koga, S, Sumiyoshi, H, Hirohata, S, Barna, BP, Germano, IM, Takakura, M, Inoue, M, Alnemri, ES, Shay, JW, Kyo, S & Kondo, S 2001, 'Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter', Cancer Research, vol. 61, no. 15, pp. 5796-5802.
Komata, T. ; Kondo, Y. ; Kanzawa, T. ; Hirohata, S. ; Koga, S. ; Sumiyoshi, H. ; Hirohata, Satoshi ; Barna, B. P. ; Germano, I. M. ; Takakura, M. ; Inoue, M. ; Alnemri, E. S. ; Shay, J. W. ; Kyo, S. ; Kondo, S. / Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. In: Cancer Research. 2001 ; Vol. 61, No. 15. pp. 5796-5802.
@article{d47ff0e2d2dc4b40ab03f9678ccb17e7,
title = "Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter",
abstract = "Because the apoptotic pathway is often disrupted in tumor cells, its genetic restoration is a very attractive approach for the treatment of tumors. To treat malignant gliomas with this approach, it would be preferred to restrict induction of apoptosis to tumor cells by establishing a tumor-specific expression system. Telomerase is an attractive target because the vast majority of malignant gliomas have telomerase activity whereas normal brain cells do not. Activation of telomerase is tightly regulated at the transcriptional level of the telomerase catalytic subunit [human telomerase reverse transcriptase, (hTERT)]. Therefore, we hypothesized that using a hTERT promoter-driven vector system, an apoptosis-inducible gene may be preferentially restricted to telomerase- or hTERT-positive tumor cells. In this study, we constructed an expression vector consisting of the constitutively active caspase-6 (rev-caspase-6) under the hTERT promoter (hTERT/rev-caspase-6) and then investigated its antitumor effect on malignant glioma cells. The rationale for using the rev-caspase-6 gene is because it induces apoptosis independent of the initiator caspases. We demonstrated that the hTERT/rev-caspase-6 construct induced apoptosis in hTERT-positive malignant glioma cells, but not in hTERT-negative astrocytes, fibroblasts, and alternative lengthening of telomeres cells. In addition, the growth of s.c. tumors in nude mice was significantly suppressed by the treatment with hTERT/rev-caspase-6 construct. The present results strongly suggest that the telomerase-specific transfer of the rev-caspase-6 gene under the hTERT promoter is a novel targeting approach for the treatment of malignant gliomas.",
author = "T. Komata and Y. Kondo and T. Kanzawa and S. Hirohata and S. Koga and H. Sumiyoshi and Satoshi Hirohata and Barna, {B. P.} and Germano, {I. M.} and M. Takakura and M. Inoue and Alnemri, {E. S.} and Shay, {J. W.} and S. Kyo and S. Kondo",
year = "2001",
month = "8",
day = "1",
language = "English",
volume = "61",
pages = "5796--5802",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter

AU - Komata, T.

AU - Kondo, Y.

AU - Kanzawa, T.

AU - Hirohata, S.

AU - Koga, S.

AU - Sumiyoshi, H.

AU - Hirohata, Satoshi

AU - Barna, B. P.

AU - Germano, I. M.

AU - Takakura, M.

AU - Inoue, M.

AU - Alnemri, E. S.

AU - Shay, J. W.

AU - Kyo, S.

AU - Kondo, S.

PY - 2001/8/1

Y1 - 2001/8/1

N2 - Because the apoptotic pathway is often disrupted in tumor cells, its genetic restoration is a very attractive approach for the treatment of tumors. To treat malignant gliomas with this approach, it would be preferred to restrict induction of apoptosis to tumor cells by establishing a tumor-specific expression system. Telomerase is an attractive target because the vast majority of malignant gliomas have telomerase activity whereas normal brain cells do not. Activation of telomerase is tightly regulated at the transcriptional level of the telomerase catalytic subunit [human telomerase reverse transcriptase, (hTERT)]. Therefore, we hypothesized that using a hTERT promoter-driven vector system, an apoptosis-inducible gene may be preferentially restricted to telomerase- or hTERT-positive tumor cells. In this study, we constructed an expression vector consisting of the constitutively active caspase-6 (rev-caspase-6) under the hTERT promoter (hTERT/rev-caspase-6) and then investigated its antitumor effect on malignant glioma cells. The rationale for using the rev-caspase-6 gene is because it induces apoptosis independent of the initiator caspases. We demonstrated that the hTERT/rev-caspase-6 construct induced apoptosis in hTERT-positive malignant glioma cells, but not in hTERT-negative astrocytes, fibroblasts, and alternative lengthening of telomeres cells. In addition, the growth of s.c. tumors in nude mice was significantly suppressed by the treatment with hTERT/rev-caspase-6 construct. The present results strongly suggest that the telomerase-specific transfer of the rev-caspase-6 gene under the hTERT promoter is a novel targeting approach for the treatment of malignant gliomas.

AB - Because the apoptotic pathway is often disrupted in tumor cells, its genetic restoration is a very attractive approach for the treatment of tumors. To treat malignant gliomas with this approach, it would be preferred to restrict induction of apoptosis to tumor cells by establishing a tumor-specific expression system. Telomerase is an attractive target because the vast majority of malignant gliomas have telomerase activity whereas normal brain cells do not. Activation of telomerase is tightly regulated at the transcriptional level of the telomerase catalytic subunit [human telomerase reverse transcriptase, (hTERT)]. Therefore, we hypothesized that using a hTERT promoter-driven vector system, an apoptosis-inducible gene may be preferentially restricted to telomerase- or hTERT-positive tumor cells. In this study, we constructed an expression vector consisting of the constitutively active caspase-6 (rev-caspase-6) under the hTERT promoter (hTERT/rev-caspase-6) and then investigated its antitumor effect on malignant glioma cells. The rationale for using the rev-caspase-6 gene is because it induces apoptosis independent of the initiator caspases. We demonstrated that the hTERT/rev-caspase-6 construct induced apoptosis in hTERT-positive malignant glioma cells, but not in hTERT-negative astrocytes, fibroblasts, and alternative lengthening of telomeres cells. In addition, the growth of s.c. tumors in nude mice was significantly suppressed by the treatment with hTERT/rev-caspase-6 construct. The present results strongly suggest that the telomerase-specific transfer of the rev-caspase-6 gene under the hTERT promoter is a novel targeting approach for the treatment of malignant gliomas.

UR - http://www.scopus.com/inward/record.url?scp=0035422652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035422652&partnerID=8YFLogxK

M3 - Article

C2 - 11479218

AN - SCOPUS:0035422652

VL - 61

SP - 5796

EP - 5802

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 15

ER -